Skip to content

Nuvation Bio NUVB Common stock, shares issued (in shares)

Common stock, shares issued (in shares) at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Tango Therapeutics logo
Tango TherapeuticsTNGX
Summit Therapeutics logo
Summit TherapeuticsSMMT
Roivant Sciences logo
Roivant SciencesROIV
Nektar Therapeutics logo
Nektar TherapeuticsNKTR

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.25B+150%

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's common stock, shares issued (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's common stock, shares issued (in shares)?
Nuvation Bio (NUVB) reported common stock, shares issued (in shares) of $337.84M in Q4 2025.
How has Nuvation Bio's common stock, shares issued (in shares) changed year-over-year?
Nuvation Bio's common stock, shares issued (in shares) decreased by 0.0% year-over-year, from $337.84M to $337.84M.
What is the long-term trend for Nuvation Bio's common stock, shares issued (in shares)?
Over 5 years (2020 to 2025), Nuvation Bio's common stock, shares issued (in shares) has grown at a 17.8% compound annual growth rate (CAGR), from $149.04M to $337.84M.